Quanterix (NASDAQ:QTRX) Announces Earnings Results

Quanterix (NASDAQ:QTRX) released its quarterly earnings data on Wednesday. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.12, Zacks reports. Quanterix had a negative return on equity of 23.55% and a negative net margin of 71.86%.The business had revenue of $35.90 million during the quarter, compared to analysts’ expectations of $36.84 million.

Here are the key takeaways from Quanterix’s conference call:

• Quanterix is increasing investment in its Alzheimer’s diagnostics business, hiring a new diagnostics leader, expanding lab infrastructure, pursuing FDA clearance for LucentAD Complete in H2 2026, and announcing a partnership with Tempus AI to integrate ordering into select EHRs.
• The company reported $36.4 million in Q1 revenue (reported +20% YoY but organic revenue declined 21%), with instrumentation sales softer than expected, 16 Simoa and 11 spatial placements, and pharma revenue down ~33% while academia represented ~65% of Q1 sales.
• Management says it has delivered the $85 million of annualized Akoya cost synergies, maintained >50% non-GAAP gross margin, narrowed adjusted EBITDA loss to $9.8 million, and ended the quarter with $102.6 million in cash and no debt while targeting cash-flow breakeven in the second half of 2026.
• Leadership is shifting from integration to growth and has launched commercial effectiveness initiatives—adding lead-generation reps, market development leaders, leveraging Thermo Fisher distribution, and prioritizing an HD?X upgrade (with an IVD filing planned in 2027) and Simoa1 early-access feedback to drive second-half revenue.
• The company changed its accounting classification for shipping and handling into cost of goods sold (affecting GAAP gross margin presentation but not non-GAAP margins) and reiterated full?year 2026 revenue guidance of $169 million–$174 million.

Quanterix Stock Up 2.9%

QTRX traded up $0.08 during trading on Friday, hitting $2.83. 2,359,120 shares of the stock were exchanged, compared to its average volume of 854,835. The firm has a market capitalization of $133.19 million, a P/E ratio of -1.20 and a beta of 1.15. Quanterix has a 1-year low of $2.56 and a 1-year high of $8.77. The stock has a fifty day moving average price of $4.11 and a two-hundred day moving average price of $5.60.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Quanterix in a report on Tuesday, April 21st. Wall Street Zen downgraded shares of Quanterix from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Canaccord Genuity Group dropped their target price on shares of Quanterix from $8.00 to $4.00 and set a “hold” rating on the stock in a research report on Monday, April 20th. Finally, TD Cowen reduced their price target on shares of Quanterix from $7.00 to $4.00 and set a “hold” rating for the company in a research report on Thursday. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Quanterix has an average rating of “Reduce” and a consensus target price of $4.00.

Hedge Funds Weigh In On Quanterix

A number of hedge funds have recently modified their holdings of QTRX. Ameriprise Financial Inc. raised its position in Quanterix by 14.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 4,236,877 shares of the company’s stock valued at $28,175,000 after purchasing an additional 521,639 shares during the last quarter. Vanguard Group Inc. grew its position in Quanterix by 4.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,647,515 shares of the company’s stock worth $14,376,000 after purchasing an additional 118,565 shares during the last quarter. Millennium Management LLC grew its position in Quanterix by 9,880.2% during the 3rd quarter. Millennium Management LLC now owns 1,209,199 shares of the company’s stock worth $6,566,000 after purchasing an additional 1,197,083 shares during the last quarter. Geode Capital Management LLC increased its stake in Quanterix by 6.1% in the fourth quarter. Geode Capital Management LLC now owns 1,073,967 shares of the company’s stock valued at $6,832,000 after purchasing an additional 62,077 shares during the period. Finally, State Street Corp increased its stake in Quanterix by 9.0% in the fourth quarter. State Street Corp now owns 893,401 shares of the company’s stock valued at $5,682,000 after purchasing an additional 73,867 shares during the period. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

Quanterix Company Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.